Boundless Bio (BOLD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 15, 2026, via live webcast for stockholders of record as of April 20, 2026.
Proxy materials, including the Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online and by request in paper or email format.
Voting matters and shareholder proposals
Stockholders will vote on the election of two director nominees: James Christensen, Ph.D., and Jennifer Lew.
Proposal to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Board recommends a vote for each director nominee and for the auditor ratification proposal.
Additional business may be transacted as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board of directors includes nominees James Christensen, Ph.D., and Jennifer Lew, up for election at the annual meeting.
Latest events from Boundless Bio
- Definitive merger with Serapha Bio triggers major restructuring, higher losses, and special dividend.BOLD
Q2 2026 - Pipeline narrows to BBI-355/BBI-825 combo and BBI-940, with cash runway into 2028.BOLD
Status Update - Advancing novel ecDNA-targeted cancer therapies with robust clinical progress and industry momentum.BOLD
Goldman Sachs 45th Annual Global Healthcare Conference - All-stock merger forms Nasdaq-listed biotech to advance AATD therapy with $230M funding.BOLD
M&A announcement - ecDNA-targeted therapies offer a novel approach for hard-to-treat oncogene amplified cancers.BOLD
Corporate presentation - Q1 2026 net loss narrowed to $13.6M; cash runway and KOMODO-1 trial support BBI-940 progress.BOLD
Q1 2026 - Stockholders will vote on director elections and auditor ratification, with strong governance in place.BOLD
Proxy filing - Phase I trial launched for a novel oral degrader targeting ecDNA-driven breast cancers.BOLD
Leerink Global Healthcare Conference 2026 - First-in-class Kinesin degrader BBI-940 targets ecDNA-driven cancers with early clinical progress.BOLD
Corporate presentation